“According to an analysis carried out by Public Health England, two doses of the Pfizer-BioNTech vaccine appeared to be about 88 percent effective against symptomatic disease and 96 percent effective against hospitalization with the delta variant.”
“A study in Israel was more of an outlier and found that the Pfizer-BioNTech vaccine did not offer as high protection as previously estimated. The study suggested the vaccine was about 64 percent effective against preventing infection with the delta variant and 64 percent effective against symptomatic illness after two doses.”
“Pfizer-BioNTech is seeking FDA approval for a booster to address waning antibody 6 months following full immunization, with particular concerns for protection against new variants.”
Due to fair use limits, please read more at:
https://www.healthline.com/health-news/heres-how-well-covid-19-vaccines-work-against-the-delta-variant#Vaccines-vs.-delta-variant